Financial Report: Alexion

Alexion

3Q Revenues: $666.6 million (+20%)

3Q Loss: $183.8 million (earnings were $177 million 3Q14)

YTD Revenues: $1.9 billion (+16%)

YTD Earnings: $77.8 billion (earnings were $503.6 million YTD14)

Comments: Soliris product sales were $665.4 million in the quarter, up 20%. Results reflect Synageva’s operations for the first full quarter following the close of the acquisition in June. Strensiq was approved by the FDA under Breakthrough Therapy Designation and Priority Review for the treatment of patients with perinatal-, infantile- and juvenile-onset hypophosphatasia (HPP). Strensiq was also approved in the EU, Japan and Canada. Restructuring expenses were $7.5 million in the quarter and includes $3.2 million resulting from the Synageva acquisition and $4.3 million related to the European headquarters relocation.